^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    OVM-200

    i
    Other names: OVM-200, OVM200, OVM 200
    Associations

    News

    Trials
    Company:
    Dx&Vx
    Drug class:
    Survivin suppressor
    Associations

    News

    Trials
    1m
    Survivin recombinant overlapping peptide (ROP) vaccine in advanced solid tumours: a first-in-human, multicentre, open-label, phase 1a dose-escalation study. (PubMed, EClinicalMedicine)
    OVM-200, a survivin recombinant overlapping peptide (ROP) vaccine, consists of overlapping peptides linked by the target sequence (LRMK) for cathepsin S, preserving T-cell and most antibody epitopes...Phase 1b is ongoing to further evaluate its safety and efficacy at the selected dose. Oxford Vacmedix UK Ltd.
    P1 data • Journal • First-in-human
    |
    BIRC5 (Baculoviral IAP repeat containing 5) • CTSS (Cathepsin S)
    |
    OVM-200
    1year
    OVM-200-100: First-in-human Study of OVM-200 As a Therapeutic Cancer Vaccine (clinicaltrials.gov)
    P1, N=36, Recruiting, Oxford Vacmedix UK Ltd. | Trial completion date: Dec 2024 --> Jan 2026 | Trial primary completion date: Dec 2024 --> Nov 2025
    Trial completion date • Trial primary completion date
    |
    OVM-200
    almost2years
    First-in-human Study of OVM-200 as a Therapeutic Cancer Vaccine (clinicaltrials.gov)
    P1, N=36, Recruiting, Oxford Vacmedix UK Ltd. | Trial completion date: Mar 2024 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    OVM-200
    almost3years
    First-in-human Study of OVM-200 as a Therapeutic Cancer Vaccine (clinicaltrials.gov)
    P1, N=36, Recruiting, Oxford Vacmedix UK Ltd. | Trial completion date: Jan 2023 --> Mar 2024 | Trial primary completion date: Dec 2022 --> Dec 2023
    Trial completion date • Trial primary completion date • Metastases
    |
    MUC16 (Mucin 16, Cell Surface Associated) • BIRC5 (Baculoviral IAP repeat containing 5)
    |
    BIRC5 expression
    |
    OVM-200
    almost4years
    First-in-human Study of OVM-200 as a Therapeutic Cancer Vaccine (clinicaltrials.gov)
    P1, N=36, Recruiting, Oxford Vacmedix UK Ltd. | Trial primary completion date: Aug 2022 --> Dec 2022
    Trial primary completion date
    |
    MUC16 (Mucin 16, Cell Surface Associated) • BIRC5 (Baculoviral IAP repeat containing 5)
    |
    BIRC5 expression
    |
    OVM-200
    over4years
    First-in-human Study of OVM-200 as a Therapeutic Cancer Vaccine (clinicaltrials.gov)
    P1, N=36, Recruiting, Oxford Vacmedix UK Ltd.
    Clinical • New P1 trial
    |
    MUC16 (Mucin 16, Cell Surface Associated) • BIRC5 (Baculoviral IAP repeat containing 5)
    |
    BIRC5 expression
    |
    OVM-200